Moffitt Experts Present Cutting Edge Radiation Oncology Research and Innovations
Thousands of radiation oncology professionals gathered in Washington, D.C., for the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting. As the world’s largest radiation oncology organization, ASTRO is dedicated to advancing the science and clinical application of radiation therapy, a treatment that contributes to 40% of cancer cures globally. This year’s meeting, centered on the theme "Targeting Provider Wellness for Exceptional Patient Care," highlights the growing recognition of health care providers' well-being as an essential element in ensuring high quality patient outcomes.
The meeting will feature groundbreaking research presentations, including studies on hypofractionated post-mastectomy radiation therapy, the efficacy of proton therapy for prostate cancer, the integration of immunotherapy with chemoradiation for small cell lung cancer and novel approaches to treating oropharyngeal cancer. Additional research will explore neurocognitive recovery following radiation treatments and address the disparities in clinical trial participation among cancer patients.
Moffitt Cancer Center’s physicians and scientists are contributing significantly to the program, with more than 25 presentations over the four-day event. Their research spans a variety of cancer types and treatment approaches, including radiomic habitat-directed and genomic-adjusted radiation dose optimization for high grade soft tissue sarcoma, combination therapy with nivolumab and androgen deprivation in prostate cancer and high dose radiotherapy for primary vulvar cancer.
To learn more about Moffitt’s presentations at ASTRO, visit www.Moffitt.org/ASTRO and read the stories below.
